● Recruiting

Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Condition: Head &Amp; Neck Squamous Cell Carcinoma · Sponsor: Tianjin Medical University Cancer Institute and Hospital

PhasePhase 2

Planned participants100

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Tianjin Medical University Cancer Institute and Hospital · +862223340123 · wxd.1133@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin 300000

Tianjin, Tianjin Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07147426